Sangamo Enterprise Value Over E B I T D A from 2010 to 2024

SGMO Stock  USD 0.49  0.03  5.77%   
Sangamo Therapeutics Enterprise Value Over EBITDA yearly trend continues to be very stable with very little volatility. Enterprise Value Over EBITDA is likely to drop to -1. During the period from 2010 to 2024, Sangamo Therapeutics Enterprise Value Over EBITDA quarterly data regression pattern had range of 243 and standard deviation of  60.79. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
(0.95)
Current Value
(1.00)
Quarterly Volatility
60.79230402
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sangamo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sangamo main balance sheet or income statement drivers, such as Interest Expense of 11.4 M, Total Revenue of 185 M or Gross Profit of 161.7 M, as well as many exotic indicators such as Price To Sales Ratio of 0.51, Dividend Yield of 0.0 or PTB Ratio of 1.09. Sangamo financial statements analysis is a perfect complement when working with Sangamo Therapeutics Valuation or Volatility modules.
  
This module can also supplement Sangamo Therapeutics' financial leverage analysis and stock options assessment as well as various Sangamo Therapeutics Technical models . Check out the analysis of Sangamo Therapeutics Correlation against competitors.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.

Latest Sangamo Therapeutics' Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Sangamo Therapeutics over the last few years. It is Sangamo Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sangamo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Sangamo Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean(27.42)
Coefficient Of Variation(221.74)
Mean Deviation30.50
Median(12.11)
Standard Deviation60.79
Sample Variance3,696
Range243
R-Value0.51
Mean Square Error2,957
R-Squared0.26
Significance0.05
Slope6.89
Total Sum of Squares51,740

Sangamo Enterprise Value Over E B I T D A History

2024 -1.0
2023 -0.95
2022 -2.12
2021 -5.2
2020 -15.51
2019 -8.58
2018 -12.96

About Sangamo Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Sangamo Therapeutics income statement, its balance sheet, and the statement of cash flows. Sangamo Therapeutics investors use historical funamental indicators, such as Sangamo Therapeutics's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Sangamo Therapeutics investors may use each financial statement separately, they are all related. The changes in Sangamo Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Sangamo Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Sangamo Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Sangamo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA(0.95)(1.00)

Currently Active Assets on Macroaxis

When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:
Check out the analysis of Sangamo Therapeutics Correlation against competitors.
To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Complementary Tools for Sangamo Stock analysis

When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.48)
Revenue Per Share
1.01
Quarterly Revenue Growth
(0.93)
Return On Assets
(0.18)
Return On Equity
(1.36)
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.